News | Clinical Decision Support | September 09, 2015

SRI International Licenses DataSpeaks Software for Virtual Clinical Decision-Making Assistant

DataSpeaks' proprietary algorithm can generate scores suggesting dose adjustments and medication switches via patient-generated and sensor data

DataSpeaks, SRI International, license, SIMA, clinical decision support

September 9, 2015 — SRI International and DataSpeaks Inc. announced that SRI has licensed the Science of Individuality Measurement Algorithm (SIMA) software from DataSpeaks. SRI will integrate SIMA into the development of a secure enterprise system for clinical decision-making.

The SIMA algorithm can transform multiple streams of patient-generated and sensor data (from wearable or implantable devices) into actionable, integrated, and personalized assessments of risks (harms) and benefits for drugs in a patient's regimen. The resulting scores may be used in the future to quickly alert healthcare practitioners about potential needs for dose adjustments and medication switches.

"The unique SIMA analytic software has the capacity to synergize with other SRI platforms as a component of an integrated enterprise system designed to enhance clinical decision-making, thereby maximizing the likelihood of treatment benefit and minimizing the risk of significant side-effects related to drugs," said David Sahner, M.D., senior director, clinical translation, SRI Biosciences. "This offers the hope of major reductions in morbidity, mortality and the over $7 billion in annual healthcare costs related to the use of potentially inappropriate medications."

The in-licensing of the software was enabled by a grant from the Michigan Economic Development Corporation to establish an inter-institutional Center of Innovation focused on personalized medicine and pharmacotherapy in the elderly.

DataSpeaks' proprietary SIMA algorithm applies to multivariate time series data that are becoming ubiquitous with hospital, home, wearable, implanted, and environmental monitoring devices; apps; electronic diaries; and pill monitors. SIMA yields internally standardized scores that quantify evidence for clinically relevant interactions over time as "edges" in network graphs that are computed from data about individual patients.

Additional potential uses of SIMA include improvement of diagnostic taxonomies that may facilitate better prediction and therapy choices, identification of disease mechanisms and new drug development targets, and use in novel clinical trial designs that do not "wash out" individual patient differences.

For more information: www.dataspeaks.com, www.sri.com

Related Content

2019 Proposed Physician Fee Schedule Appropriate Use Criteria Summary
Feature | Clinical Decision Support | July 13, 2018 | Nathan Baugh
On July 12, the Centers for Medicare and Medicaid Services (CMS) released the proposed rule for the 2019 Physician Fe
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Videos | Clinical Decision Support | March 22, 2018
Jonathan Teich, M.D., chief medical information officer for InterSystems, discusses the growth of clinical decision s
Siemens Healthineers Launches New Partners for Digital Ecosystem at HIMSS 2018
News | PACS Accessories | March 12, 2018
At the 2018 Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition, March 5-9...
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
FDA Clears First AI-Powered Clinical Decision Support Software for Stroke
Technology | Clinical Decision Support | February 14, 2018
The U.S. Food and Drug Administration (FDA) announced marketing clearance for Viz.AI’s Contact application, the first ...
Elekta and IBM Watson Health Bringing Artificial Intelligence to Oncology
News | Oncology Diagnostics | January 31, 2018
Elekta announced it is collaborating with IBM Watson Health to offer Watson for Oncology with Elekta’s cancer care...
MedCurrent Rolls Out OrderWise Clinical Decision Support Platform With iRefer Guidelines
Technology | Clinical Decision Support | January 29, 2018
Primary care providers and hospital doctors around the world can now access the imaging referral guidelines from the U....
National Clinical Decision Support Company (NDSC) has an exclusive deal with the American College of Radiology (ACR) to provide medical imaging appropriate use criteria (AUC).

National Clinical Decision Support Company (NDSC) has an exclusive deal with the American College of Radiology (ACR) to provide medical imaging appropriate use criteria (AUC). 

Feature | Clinical Decision Support | January 18, 2018
January 18, 2018 — Change Healthcare announced the acquisition of National Decision Support Company (NDSC), a leader
News | Clinical Decision Support | January 12, 2018
January 12, 2018 — GE Healthcare has entered into a strategic, long-term partnership with Roche to jointly develop an
Overlay Init